ATC Group: G04CB02 Dutasteride

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04CB02 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04C Drugs used in benign prostatic hypertrophy
4 G04CB Testosterone-5-alpha reductase inhibitors
5 G04CB02 Dutasteride

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.5 mg

Active ingredients in G04CB02

Active Ingredient Description
Dutasteride

Dutasteride reduces circulating levels of dihydrotestosterone (DHT) by inhibiting both type 1 and type 2, 5α-reductase isoenzymes which are responsible for the conversion of testosterone to DHT.

Related product monographs

Title Information Source Document Type  
Avodart 0.5mg soft capsules Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Albania (AL)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Singapore (SG)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.